ArticleScientific reports2025
Lipid membrane-camouflaged biomimetic nanoparticle for MicroRNA based therapeutic delivery to intestinal epithelial cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functional Reclassification of Lipid-Based Drug Delivery Systems and Advances in Formulation Strategies and Manufacturing Challenges.AAPS PharmSciTech · 2026Review
- MicroRNA‑microbiome cross‑kingdom networks drive inflammatory bowel disease through dynamic regulatory ecosystems (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We have made artificial extracellular vesicles like nanoparticles that contain biologically active Agomir (miRNA mimic)/Antagomir (miRNA inhibitor) adsorbed on magnetic ZnO particles bound by a lipid bilayer membrane from Caco-2 cells (human colorectal adenocarcinoma), which we examined for use as therapeutic nanoparticles or as delivery vehicles for therapeutic agents to the gut epithelia. Magnetic ZnO nanoparticles were synthesized using Manganese doping in both solid-state reaction (SSR) and alkaline aqueous solution methods. The SSR method exhibited ferromagnetic behavior, whereas the alkaline solution method yielded a nanorod-like morphology. Encapsulation was demonstrated using mercaptosuccinic acid. These biocompatible nanoparticles, owing to their nanorod-like morphology with larger surface area, were used to adsorb miR200c antagomir/agomir molecules as well as assemble lipid membrane fragments from Caco-2 cells. We performed various in vivo efficacy studies of Caco-2 NanoVesicles (CNVs) (Caco-2NanoVesicles) or detrimental CNV (therapeutic Caco-2 NanoVesicles (tCNVs)) loaded with miR200c Agomir that degrade occludin protein-coding mRNA as a proof of concept for clinical use of the Antagomir counterpart. There was no discernible toxicity, mortality, or systemic inflammatory or immunological responses in mice following administration of either CNVs or tCNVs. tCNV administration enhances intestinal permeability in mice. This supports their use as biological Nano-therapeutics to restore the gut barrier.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.